Good morning :)
$
₹
H

HELUS+PHARMA+INC

HELP

US
H

HELUS+PHARMA+INC

HELP

US
$10.584.22% (-0.46)
$
₹
$10.584.22% (-0.46)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $758.4M the stock is ranked 2922

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.92
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-4.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 11 analysts reports

Buy
11 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+281.69%

Earnings Growth

+25.6%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
39.15
39.15
1Y Return
53.63%
53.63%
Buy Reco %
83.33
83.33
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
28.82
28.82
1Y Return
33.86%
33.86%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
116.96
116.96
1Y Return
73.91%
73.91%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
21.50
21.50
1Y Return
15.17%
15.17%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
24.21
24.21
1Y Return
2.19%
2.19%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$10.55Baseline
Analyst Target - 1 year
Target$40.27+281.69%

All values in $

20232024202520262027$18.20$26.90$35.60Target+281.69%
2026
Current$10.55Baseline
Analyst Target - 1 year
Target$40.27+281.69%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2026
Current$-5Baseline
Forecast for Mar 2027
High$-2.86+42.82%
Average$-3.72+25.6%
Low$-4.43+11.46%

All values in $

202220232024202520262027-14.59-8.55-8.77-5.61-5Low+11.46%Average+25.6%High+42.82%
2026
Current$-5Baseline
Forecast for Mar 2027
High$-2.86+42.82%
Average$-3.72+25.6%
Low$-4.43+11.46%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-47
-42.6
1.2
-46.9
-46.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue--0000001.290
Net Income-21.34-10.83-56.89-10.84-30.57-24.60-47.03-42.63-46.99-46.60
Net Profit Margin---------3617.81%-
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
HELUS+PHARMA+INC -3.92-
Eli Lilly and Company39.1530.281.13
Johnson & Johnson28.827.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare HELP with any stock or ETF
Compare HELP with any stock or ETF
Comparing from
HELP
LLY
JNJ
Loading...

Frequently asked questions

  1. HELUS+PHARMA+INC (HELP) share price today is $10.58 as of October 17, 2026 at 1:30 AM IST. The stock touched a day high of $10.93 and a day low of $10.44.

  2. HELUS+PHARMA+INC stock trades on US under the ticker symbol HELP.

  3. HELUS+PHARMA+INC's market capitalization is $758.36M as of October 17, 2026 at 1:30 AM IST.

  4. HELUS+PHARMA+INC's price-to-earnings (P/E) ratio is N/A as of October 16, 2026.

  5. HELUS+PHARMA+INC's price-to-book (P/B) ratio is 3.92 as of October 16, 2026.

  6. Yes, You can buy HELUS+PHARMA+INC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy HELUS+PHARMA+INC shares in three steps: 1. Search HELUS+PHARMA+INC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since HELUS+PHARMA+INC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in HELUS+PHARMA+INC (HELP) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.9449 shares at the current price of $10.58.

Loading...